HK1097860A1 - Compounds for proteasome enzyme inhibition - Google Patents

Compounds for proteasome enzyme inhibition

Info

Publication number
HK1097860A1
HK1097860A1 HK07105045.7A HK07105045A HK1097860A1 HK 1097860 A1 HK1097860 A1 HK 1097860A1 HK 07105045 A HK07105045 A HK 07105045A HK 1097860 A1 HK1097860 A1 HK 1097860A1
Authority
HK
Hong Kong
Prior art keywords
peptide
compounds
based compounds
activities
ntn
Prior art date
Application number
HK07105045.7A
Other languages
English (en)
Inventor
Mark S Smyth
Guy J Laidig
Ronald T Borchardt
Barry A Bunin
Craig M Crews
John H Musser
John S Schneekloth Jr
John Clifford Chabala
Original Assignee
Proteolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1097860(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proteolix Inc filed Critical Proteolix Inc
Publication of HK1097860A1 publication Critical patent/HK1097860A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
HK07105045.7A 2004-04-15 2007-05-14 Compounds for proteasome enzyme inhibition HK1097860A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56234004P 2004-04-15 2004-04-15
US56909604P 2004-05-07 2004-05-07
US59940104P 2004-08-06 2004-08-06
US61000204P 2004-09-14 2004-09-14
US61015904P 2004-09-14 2004-09-14
US61000104P 2004-09-14 2004-09-14
US62057304P 2004-10-20 2004-10-20
PCT/US2005/012740 WO2005105827A2 (en) 2004-04-15 2005-04-14 Compounds for proteasome enzyme inhibition

Publications (1)

Publication Number Publication Date
HK1097860A1 true HK1097860A1 (en) 2007-07-06

Family

ID=34965899

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105045.7A HK1097860A1 (en) 2004-04-15 2007-05-14 Compounds for proteasome enzyme inhibition

Country Status (18)

Country Link
US (9) US8129346B2 (da)
EP (1) EP1745064B1 (da)
JP (3) JP5616569B2 (da)
CN (2) CN103554222A (da)
AT (1) ATE494298T1 (da)
AU (1) AU2005238445B2 (da)
BE (1) BE2016C014I2 (da)
BR (1) BRPI0509879A (da)
CA (1) CA2562411A1 (da)
CY (1) CY1117244T1 (da)
DE (1) DE602005025750D1 (da)
DK (1) DK1745064T3 (da)
HK (1) HK1097860A1 (da)
IL (3) IL178400A (da)
PL (1) PL1745064T3 (da)
PT (1) PT1745064E (da)
SG (2) SG185306A1 (da)
WO (1) WO2005105827A2 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
EP1745064B1 (en) 2004-04-15 2011-01-05 Proteolix, Inc. Compounds for proteasome enzyme inhibition
AU2012203602B2 (en) * 2004-04-15 2015-08-27 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
PL2030981T3 (pl) 2004-05-10 2014-12-31 Onyx Therapeutics Inc Związki do enzymatycznej inhibicji proteasomu
US7737112B2 (en) * 2004-12-07 2010-06-15 Onyx Therapeutics, Inc. Composition for enzyme inhibition
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
JP5226679B2 (ja) * 2006-06-19 2013-07-03 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
EA024437B1 (ru) 2007-10-04 2016-09-30 Оникс Терапьютикс, Инк. Синтез кето-эпоксидов аминокислот
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
EP2408802B1 (en) 2009-03-16 2017-05-03 The Governing Council of the University of Toronto Cyclic amino acid molecules and methods of preparing the same
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US10159746B2 (en) * 2012-05-08 2018-12-25 Onyx Therapeutics, Inc. Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
PT2968555T (pt) 2013-03-13 2020-07-14 Univ California Composições compreendendo anticorpos anti-cd38 e carfilzomib
US20160166632A1 (en) 2013-07-19 2016-06-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CA2922210A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
CN105518019A (zh) * 2013-09-06 2016-04-20 桑多斯股份公司 肽环氧基酮的合成
CN104710507B (zh) * 2013-12-11 2018-08-14 深圳翰宇药业股份有限公司 一种卡非佐米的制备方法
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
JP6608442B2 (ja) 2014-07-14 2019-11-20 セントラックス インターナショナル，インコーポレイテッド 酵素阻害に用いられるエポキシケトン化合物
WO2016046843A1 (en) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en) 2014-10-27 2016-05-06 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CN107548400A (zh) 2014-12-02 2018-01-05 费森尤斯卡比肿瘤学有限公司 卡非佐米的纯化方法
WO2016108204A1 (en) 2014-12-31 2016-07-07 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
WO2016170544A1 (en) * 2015-04-22 2016-10-27 Msn Laboratories Private Limited Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016170489A1 (en) 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of proteasome inhibitor
WO2016185450A1 (en) 2015-05-21 2016-11-24 Laurus Labs Private Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
AU2016353547B9 (en) 2015-11-11 2020-12-03 Universite De Montreal Cyclic peptides targeting α4β7 integrin
EP3494126A1 (en) 2016-08-02 2019-06-12 Synthon BV Process for making carfilzomib
WO2018051237A1 (en) 2016-09-14 2018-03-22 Fresenius Kabi Oncology Limited A process for purification of carfilzomib intermediate
CA3042576A1 (en) 2016-11-11 2018-05-17 Encycle Therapeutics, Inc. Cyclic peptides multimers targeting .alpha.4.beta.7 integrin
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
CN106946981B (zh) * 2017-03-08 2020-08-21 南京陵瑞医药科技有限公司 一种四肽环氧丙烷衍生物及其制备方法和用途
IL270465B (en) 2017-05-10 2022-09-01 Encycle Therapeutics Inc Cyclic peptides targeting alpha4beta7 integrin
WO2019053611A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
CN113185575B (zh) * 2021-05-11 2022-07-12 四川大学 一种花生抗氧化多肽及其制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH01136498A (ja) 1987-11-21 1989-05-29 Nec Corp 状態監視用情報伝送装置
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) * 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
EP1136498A1 (en) 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
ES2169880T3 (es) * 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
AU729793B2 (en) 1996-12-13 2001-02-08 Zymogenetics Inc. Compositions and methods for stimulating bone growth
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
JP4439596B2 (ja) * 1997-06-13 2010-03-24 サイデクス ファーマシューティカルズ、 インク． 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
JP4503182B2 (ja) * 1998-10-20 2010-07-14 ミレニアム・ファーマシューティカルズ・インコーポレイテッド プロテアソーム・インヒビター薬物作用のモニター方法
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
EP1221962A2 (en) 1999-10-20 2002-07-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
AU2002218133A1 (en) * 2000-10-12 2002-04-22 Viromics Gmbh Agents for the treatment of viral infections
EP1463719A2 (en) * 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
EP1496916A2 (en) * 2002-04-09 2005-01-19 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US20030224469A1 (en) * 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
EP1745064B1 (en) * 2004-04-15 2011-01-05 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
PL2030981T3 (pl) * 2004-05-10 2014-12-31 Onyx Therapeutics Inc Związki do enzymatycznej inhibicji proteasomu
EP1805208A2 (en) * 2004-10-20 2007-07-11 Proteolix, Inc. Labeled compounds for proteasome inhibition
US7737112B2 (en) * 2004-12-07 2010-06-15 Onyx Therapeutics, Inc. Composition for enzyme inhibition
EP1863513A2 (en) * 2005-03-11 2007-12-12 The University of North Carolina at Chapel Hill Potent and specific immunoproteasome inhibitors
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
JP5226679B2 (ja) * 2006-06-19 2013-07-03 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
JP4325683B2 (ja) * 2007-02-14 2009-09-02 セイコーエプソン株式会社 画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
EA024437B1 (ru) 2007-10-04 2016-09-30 Оникс Терапьютикс, Инк. Синтез кето-эпоксидов аминокислот
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo

Also Published As

Publication number Publication date
BRPI0509879A (pt) 2007-10-16
AU2005238445B2 (en) 2012-05-03
US20080200398A1 (en) 2008-08-21
US8207127B2 (en) 2012-06-26
WO2005105827A2 (en) 2005-11-10
JP2014012676A (ja) 2014-01-23
CA2562411A1 (en) 2005-11-10
US8207126B2 (en) 2012-06-26
JP2012041346A (ja) 2012-03-01
US20120277146A1 (en) 2012-11-01
WO2005105827A3 (en) 2006-03-30
US20120101048A1 (en) 2012-04-26
US8324174B2 (en) 2012-12-04
IL217210A0 (en) 2012-01-31
US8207124B2 (en) 2012-06-26
DE602005025750D1 (de) 2011-02-17
US20120094928A1 (en) 2012-04-19
IL178400A (en) 2012-02-29
US20130324459A1 (en) 2013-12-05
IL217211A0 (en) 2012-01-31
JP5616569B2 (ja) 2014-10-29
CN103554222A (zh) 2014-02-05
DK1745064T3 (da) 2011-04-11
US20120101050A1 (en) 2012-04-26
US20120094926A1 (en) 2012-04-19
BE2016C014I2 (da) 2024-10-09
PT1745064E (pt) 2011-03-23
US8207125B2 (en) 2012-06-26
SG152239A1 (en) 2009-05-29
EP1745064B1 (en) 2011-01-05
IL178400A0 (en) 2007-02-11
PL1745064T3 (pl) 2011-06-30
US20120094929A1 (en) 2012-04-19
US8129346B2 (en) 2012-03-06
JP2008501637A (ja) 2008-01-24
CN102174076A (zh) 2011-09-07
ATE494298T1 (de) 2011-01-15
US8207297B2 (en) 2012-06-26
CY1117244T1 (el) 2017-04-05
US20120094930A1 (en) 2012-04-19
AU2005238445A1 (en) 2005-11-10
SG185306A1 (en) 2012-11-29
EP1745064A2 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
HK1231491A1 (zh) 用於抑制蛋白酶體的化合物
IL217211A0 (en) Compounds for proteasome enzyme inhibition
EP2564834A3 (en) Compounds for Proteasome Enzyme Inhibition
MY145757A (en) Compounds for enzyme inhibition
WO2008140782A3 (en) Compounds for enzyme inhibition